Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart failure drug shows promise in hospitalized patients

NCT ID NCT06815471

Disease control Sponsor: Corteria Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests an investigational drug called COR-1167 in 300 people hospitalized with worsening heart failure. Participants receive either the drug or a placebo for 28 days. Researchers measure how well the body removes fluid, changes in weight, heart function, and symptoms. The goal is to see if COR-1167 can improve recovery and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COR-1167
What this could lead to
If successful, this could lead to a new treatment option for people hospitalized with worsening heart failure, helping them recover faster and feel better.
What could go wrong
This is an early Phase 2 trial with only 300 participants, so results may not apply to all heart failure patients. The drug may not work better than standard care or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed written informed consent * Heart failure hospitalization (HFH) during previous 12 months * Prescribed an oral loop diuretic for at least 1 month preceding the index event * NT-proBNP ≥1,000 pg/mL or BNP ≥250 pg/mL * Requires treatment with i.v. diuretics for volume overload * At least 1 risk factor for diuretic resistance * Admitted to the hospital not more than 48 hours prior to randomization Exclusion Criteria: * Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia) * Requirement for i.v. inotropic therapy or i.v. vasodilators, mechanical ventilation, high-flow oxygen therapy, or NIV * Requirement for, or planned use of LVADs, IABP, or any type of MCS * History of solid organ transplant or active on a transplant list * SBP \<100 mmHg * eGFR \< 20 mL/min/1.73 m2 * CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study * Severe stenotic cardiac valvular disease * Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (\> 2 L/min) * Uncorrected severe hyperthyroidism or hypothyroidism * Severe restrictive, obstructive, or infiltrative cardiomyopathy * Body weight \< 70 kg * Use of any investigational drug(s) within 5 half-lives of screening * At high risk of death (defined as life expectancy ≤1 year) from causes other than heart failure or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult * Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Worsening heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

advanced heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Worsening heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    55 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research

    Tbilisi, 0159, Georgia

  • Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials

    Tbilisi, 0159, Georgia

  • Aleksandre Aladashvili Clinic LLC

    Tbilisi, 0102, Georgia

  • Bokhua Memorial Cardiovascular Center LTD

    Tbilisi, 0159, Georgia

  • Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály

    Budapest, 1145, Hungary

  • Clinical Hospital Center "Dr Dragisa Misovic Dedinje"

    Belgrade, 11000, Serbia

  • Cone Health Moses Cone Hospital

    Greensboro, North Carolina, 27401, United States

  • Consorcio Hospital General Universitario de Valencia

    Valencia, 46014, Spain

  • Craiova County Emergency Clinical Hospital

    Craiova, 200642, Romania

  • Emergency County Clinical Hospital Arad, Cardiology department

    Arad, 310037, Romania

  • Fakultní nemocnice Brno

    Brno, 62500, Czechia

  • Fakultní nemocnice Ostrava

    Ostrava, 70852, Czechia

  • General Hospital Leskovac, Cardiology Department

    Leskovac, 16000, Serbia

  • Georgian Dutch Hospital

    Tbilisi, 0167, Georgia

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar, Murcia, 30120, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, 46010, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitario Hospital Virgen del Rocío

    Seville, 41013, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Ramon y Cajal

    Fuencarral-El Pardo, Madrid, 28034, Spain

  • I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne

    Gdansk, 80-214, Poland

  • II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi

    Lodz, 92-213, Poland

  • Indiana University Health Methodist Hospital

    Indianapolis, Indiana, 46202, United States

  • Institute For Treatment and Rehabilitation "Niska Banja"

    Niška Banja, 18205, Serbia

  • Institute for Cardiovascular Diseases Dedinje

    Belgrade, 11000, Serbia

  • Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 1

    Bucharest, 022328, Romania

  • Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 3

    Bucharest, 022328, Romania

  • Instytut Chorób Serca, Zakład Badań Klinicznych Chorób Układu Krążenia, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

    Wroclaw, 50-556, Poland

  • Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w Rzeszowie

    Rzeszów, 35-301, Poland

  • Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku

    Bialystok, 15-276, Poland

  • LTD "Israeli-Georgian Medical Research Clinic Healthycore"

    Tbilisi, 0112, Georgia

  • LTD Tbilisi Heart Center

    Tbilisi, 0186, Georgia

  • NC Heart and Vascular Research, LLC

    Raleigh, North Carolina, 27607, United States

  • Nemocnice Slaný

    Slaný, 27401, Czechia

  • Oddział Kliniczny Kardiologii i Intensywnej Terapii Kardiologicznej

    Torun, 87-100, Poland

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika

    Pécs, 7624, Hungary

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    Krakow, 30-688, Poland

  • Sdružené zdravotnické zařízení Krnov

    Krnov, 79401, Czechia

  • Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika

    Budapest, 1122, Hungary

  • South Oklahoma Heart Research, LLC

    Oklahoma City, Oklahoma, 73135, United States

  • Spitalul Clinic Colentina

    Bucharest, 20125, Romania

  • Spitalul Clinic Municipal de Urgenta Timisoara

    Timișoara, 300079, Romania

  • St. Michael's Hospital LLC

    Tbilisi, 0159, Georgia

  • Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet

    Szeged, 7625, Hungary

  • Tbilisi Heart and Vascular Clinic, LTD

    Tbilisi, 0159, Georgia

  • University Clinical Center Kragujevac, Clinic for Cardiology

    Kragujevac, 34000, Serbia

  • University Clinical Center Nis, Clinic for Cardiology

    Niš, 18000, Serbia

  • University Clinical Center of Serbia, Clinic for Cardiology, Department for the testing and treatment of congenital and acquired heart defects

    Belgrade, 11000, Serbia

  • University Clinical Center of Serbia, Clinic for Cardiology, Emergency Cardiology Department

    Belgrade, 11000, Serbia

  • University Clinical Center of Serbia, Clinic for Cardiology, Heart Failure Ward

    Belgrade, 11000, Serbia

  • Wayne State University - Detroit Receiving Hospital

    Detroit, Michigan, 48201, United States

  • Wayne State University - Sinai Grace Hospital

    Detroit, Michigan, 48235, United States

  • Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály

    Zalaegerszeg, 8900, Hungary

  • Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii

    Kłodzko, 57-300, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.